Key takeaway
In 74 people with fatty liver (NAFLD), 12 weeks of a 5:2 diet or a low-carb high-fat diet reduced liver fat by 6.1% and 7.2% in absolute terms, versus 3.6% with general lifestyle advice. The trial was open-label and small, so it cannot tell us whether the benefit lasts beyond 12 weeks.
Study design
Randomised trial
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
The research question
Weight loss is the first-line treatment for non-alcoholic fatty liver disease (NAFLD), but popular diets have rarely been tested for their direct effect on liver fat. The authors compared intermittent calorie restriction (the 5:2 diet) with a low-carb high-fat (LCHF) diet for reducing liver fat.
Who and how
Open-label randomised controlled trial of 74 patients with NAFLD, assigned 1:1:1 to a LCHF diet, a 5:2 diet, or general lifestyle advice from a hepatologist (standard of care, SoC) for 12 weeks. The primary outcome was liver fat (hepatic steatosis) measured by magnetic resonance spectroscopy. Secondary outcomes included transient elastography (liver stiffness), insulin resistance, blood lipids and body measurements. The trial is registered as NCT03118310.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Both diets lowered liver fat more than standard advice. Absolute reductions were 7.2% (95% CI -9.3 to -5.1) for LCHF, 6.1% (95% CI -8.1 to -4.2) for 5:2 and 3.6% (95% CI -5.8 to -1.5) for SoC.
- 2Body weight fell by 7.3 kg (95% CI -9.6 to -5.0) on LCHF and 7.4 kg (95% CI -8.7 to -6.0) on 5:2, compared with 2.5 kg (95% CI -3.5 to -1.5) with SoC.
- 3The two diets did not differ from each other for liver fat (p = 0.41) or weight (p = 0.78).
- 4Liver stiffness improved in the 5:2 and SoC groups but not in the LCHF group. The 5:2 diet was associated with lower LDL cholesterol and was tolerated better than LCHF.
Limits & uncertainty
- 1Only 74 people were randomised across three groups, and the abstract does not report how many finished.
- 2Participants knew their diet (open-label), and the comparison group received only general advice, not a structured programme.
- 3Follow-up was 12 weeks, so durability of weight and liver-fat changes is unknown.
- 4The liver stiffness and LDL results are secondary outcomes. This reading is based on the abstract only.
What to take from it
For people with fatty liver, both a 5:2 pattern and a low-carb high-fat pattern produced meaningful weight and liver-fat reductions in this trial, and the authors suggest choosing the one a person can stick with. It does not show either diet is safe or suitable for everyone; diet changes for liver disease should be discussed with a clinician.
Reading your own data
Body weight trends from a home scale are the most relevant personal measure here; weigh at the same time of day under similar conditions and watch the multi-week trend. Liver fat and stiffness require imaging and cannot be tracked at home.
How to read this evidence
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background & aims
The first-line treatment for non-alcoholic fatty liver disease (NAFLD) is weight reduction. Several diets have been proposed, with various effects specifically on liver steatosis. This trial compared the effects of intermittent calorie restriction (the 5:2 diet) and a low-carb high-fat diet (LCHF) on reduction of hepatic steatosis.
Methods
We conducted an open-label randomised controlled trial that included 74 patients with NAFLD randomised in a 1:1:1 ratio to 12 weeks' treatment with either a LCHF or 5:2 diet, or general lifestyle advice from a hepatologist (standard of care; SoC). The primary outcome was reduction of hepatic steatosis as measured by magnetic resonance spectroscopy. Secondary outcomes included transient elastography, insulin resistance, blood lipids, and anthropometrics.
Results
The LCHF and 5:2 diets were both superior to SoC treatment in reducing steatosis (absolute reduction: LCHF: -7.2% [95% CI = -9.3 to -5.1], 5:2: -6.1% [95% CI = -8.1 to -4.2], SoC: -3.6% [95% CI = -5.8 to -1.5]) and body weight (LCHF: -7.3 kg [95% CI = -9.6 to -5.0]; 5:2: -7.4 kg [95% CI = -8.7 to -6.0]; SoC: -2.5 kg [95% CI =-3.5 to -1.5]. There was no difference between 5:2 and LCHF ( p = 0.41 for steatosis and 0.78 for weight). Liver stiffness improved in the 5:2 and SoC but not in the LCHF group. The 5:2 diet was associated with reduced LDL levels and was tolerated to a higher degree than LCHF.
Conclusions
The LCHF and 5:2 diets were more effective in reducing steatosis and body weight in patients with NAFLD than SoC, suggesting dietary advice can be tailored to meet individual preferences.
Lay summary
For a person with obesity who suffers from fatty liver, weight loss through diet can be an effective treatment to improve the condition of the liver. Many popular diets that are recommended for weight reduction, such as high-fat diets and diets based on intermittent fasting, have not had their effects on the liver directly evaluated. This study shows that both a low-carb high-fat and the 5:2 diet are effective in treating fatty liver caused by obesity.
Clinical trials registration
This study is registered at Clinicaltrials.gov (NCT03118310).
Sources & attribution
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial.
Holmer M, Lindqvist C, Petersson S, Moshtaghi-Svensson J, Tillander V, Brismar TB, Hagström H, Stål P.
JHEP reports : innovation in hepatology · 2021-02-17
DOI: 10.1016/j.jhepr.2021.100256 ↗PubMed · 33898960 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

